Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome

NCT00546052 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT00546052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00546052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome
Lead sponsor
Organon and Co
Phase
Phase 3
Overall status
Completed
Start date
September 1, 2005
Completion date
January 1, 2008
Enrollment
1,738 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, metabolic disorder